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Abstract
Introduction
Appropriate algorithms for the prediction of cardiovascular risk are strongly suggested in
clinical practice, although still controversial. In type 2 diabetes mellitus (T2DM), the benefi-
cial effect of phosphodiesterase (PDE)-5 inhibitors is demonstrated on endothelial function
but not on the estimation of cardiovascular risk.
Aim
To study whether the chronic Vardenafil administration to men with T2DM influences vari-
ables correlated with the predicted long-term cardiovascular risk calculated by different vali-
dated algorithms.
Methods
Per-protocol analysis of a longitudinal, prospective, randomized, placebo-controlled, dou-
ble-blind, investigator-started, clinical trial. 54 male patients affected by T2DM were
assigned to study (26patients) and control-group (28patients), respectively. The study
included a treatment phase (24weeks) (Vardenafil/placebo 10mg twice-daily) and a follow-
up phase (24weeks). Three time points were considered: baseline(V0), end of treatment
(V1) and end of the study(V2). Parameters evaluated: endothelial health-related parameters
and cardiovascular risk, assessed by calculating the Framingham (coronary hart disease
[CHD], myocardial infarction [MI], stroke and cardiovascular disease [CVD]), ASSIGN and
CUORE equations.
Results
Predicted cardiovascular risk at ten years resulted different using the three algorithms cho-
sen, without differences between study and control groups and among visits. IL-6 was
directly related to CHD, CVD and CUORE scores at V1 and with MI and STROKE at V2.
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Similarly, hs-CRP was directly related to CHD, MI, STROKE and CUORE only at V1 in the
study group. Testosterone serum levels were inversely related to CHD and MI at V1 in study
group.
Discussion
The predicted cardiovascular risk is different depending on the algorithm chosen. Despite
no predictive risk reduction after six months of treatment, a possible effect of Vardenafil
could be hypothesized through its action on inflammation markers reduction and through
restoration of normal testosterone levels.
Introduction
Predictability of coronary heart diseases (CHD) is one of the major challenge in clinical prac-
tice [1–4]. Cardiology societies worldwide recommend the use of appropriate predictive algo-
rithms for identification of patients at high cardiovascular risk [5–10]. The Framingham Heart
study provided the first and best known example of such equations, created in 1991 thanks to a
large North American population-based trial [11]. This algorithm is used to calculate the car-
diovascular risk at ten years with the final aim to decide if a preventive treatment is needed
[11]. A number of algorithms have been proposed in the following years, considering the pop-
ulation-specific risk and evaluating different large population-based cohorts. For the Italian
population, in 2000, the CUORE score was created to evaluate the risk of coronary deaths [12–
14]. These algorithms represent the only largely evaluated method to consider this risk in a
cohort of patients.
Type 2 diabetes mellitus is one of the major risk factors of CHD [15]. Indeed, diabetes
increases the long-term cardiovascular risk to the level observed in non-diabetic patients with
prior myocardial infarction [16]. Diet, exercise, anti-diabetic drugs and bariatric surgery
approaches have been studied for their effectiveness in reducing cardiovascular events, which
is generally independent on their glucose-lowering effect [15]. In this clinical setting, despite
the validation of multiple diabetes-specific and general population-based cardiovascular risk
assessment models, the cardiovascular risk estimation remains approximate [17]. Moreover,
the management of diabetic men does not always consider prediction of cardiovascular risk in
the treatment selection.
Phosphodiesterase (PDE)-5 inhibitors are approved for erectile dysfunction and for pulmo-
nary hypertension. These drugs act controlling the intra-cellular degradation rate of second
messengers, such as cyclic guanosine monophosphate (cGMP) [18]. Consequently, PDE-5
inhibitors improve vasodilation, through the nitric oxide (NO)-dependent cGMP increase [19,
20]. This vasodilator effect has been studied at cardiovascular level, evaluating the cardiac out-
put in case of chronic congestive heart failure [21], the remodelling action on the cardiac mus-
cle cells, as well as the inhibition of platelet aggregation [22]. All these effects are due to the
restoration of the physiologic equilibrium between mediators of vasoconstriction and vasodila-
tion, inhibiting the catabolism of cGMP and enhancing NO levels [23]. These endothelial func-
tion improvements could reduce atherogenesis and vascular complications of diabetes mellitus
[23]. Despite an increasing evidence of these beneficial effects [24], no studies so far evaluated
whether PDE-5 inhibitors administration influences the long-term cardiovascular risk predic-
tion in diabetic patients.
PDE-5 inhibitors and cardiovascular risk
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In this study we assessed whether the chronic Vardenafil administration to men with type 2
diabetes mellitus could reduce the long-term estimated cardiovascular risk, using validated
algorithms. Since no specific algorithm to predict cardiovascular risk in diabetic men is com-
monly accepted as the reference method so far, three different equations were used and
compared.
Materials and methods
Study design
This is a secondary, retrospective, analysis of a recent longitudinal, prospective, randomized,
placebo-controlled, double-blind, investigator-started, clinical trial described in detail earlier
[25]. Briefly, we enrolled 54 patients with diagnosis of type 2 diabetes mellitus made within 5
years before enrollment, and with erectile dysfunction but no previous use of PDE-5 inhibitors
(Fig 1). The study lasted from 2008 to 2014. Patients were randomized using the permuted
block method and assigned to the study or control group, in which Vardenafil (10 mg twice
daily) or placebo were administered, respectively [25]. Patients were followed for one year,
considering six months of therapy and six months of treatment withdrawal. During the year of
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0199299.g001
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trial, each patient was evaluated ten times, 8 during the treatment phase and 2 during the fol-
low-up [25]. During each visit, a blood sample was taken after an overnight fast and biochemi-
cal and endothelial health-related parameters were evaluated and reported in our previous
paper [25]. Here, we used biochemical parameters and clinical history of the patients to calcu-
late the cardiovascular risk using three different validated algorithms. In particular, using a
per-protocol analysis, we considered three visits carried out six months away: baseline (V0),
end of treatment (V1) and end of the study (V2).
Cardiovascular risk assessment
The cardiovascular risk was calculated using three appropriate validated algorithms available
in the literature. First, the Framingham algorithm [11] was used, which considers the four fol-
lowing outcome risks: CHD, myocardial infarction (MI), stroke and cardiovascular disease
(CVD). Second, the ASSIGN equation and the CUORE score were used as alternative tools to
cardiovascular risk calculation. The ASSIGN risk score derives from the Scottish Heart Health
Extended cohort study, which includes several cohorts with more than 6000 men aged between
30 and 74 years [26]. The CUORE risk score [27–29] derives from a study including a combi-
nation of 11 Italian cohorts with more than 6800 men aged between 35 and 69 years [14].
Overall, these three tools predict the cardiovascular risk considering age, sex, total choles-
terol, HDL, diabetes mellitus, smoking habit and systolic pressure.
Cardiovascular and biochemical parameters
The calculated cardiovascular risk was evaluated in association with markers of endothelial
health. In particular, we considered ultrasonography parameters, such as flow mediated dila-
tion (FMD) [30, 31], and biochemical markers, such as interleukin (IL)-6, intercellular adhe-
sion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, high sensitivity C-
reactive protein (hs-CRP), endothelin (ET)-1 and testosterone serum levels.
IL-6 was measured on plasma samples by the Human IL-6 Quantikine ELISA Kit (R&D
Systems Europe, Ltd. Abingdon OX14 3NB, UK). ICAM-1 and VCAM-1 were measured on
serum samples, diluted 1:2, using the bead-based multiplex assay for Luminex platform (R&D
Systems Inc kit code LXSAH, Minneapolis, US). Hs-CRP and ET-1 were measured with the
BN™ II System instrument (Siemens) through a specific automated nephelometric assay (Car-
dioPhase1 hsCRP, Dada Behring Inc. Newark, DE 19714 US). Testosterone was analyzed by
liquid-chromatography, tandem mass-spectometry (LC/MS-MS) (Shimadzu Nexera UHPLC
with Shimadzu LCMS-8050 triple quadrupole) with the Pelkin Elmer kit (Wallac OY, Turku,
Finland), using serum samples obtained at each visit. Other routine assays were performed
using commercially available kits.
Ethics
The local Ethics Committee of the University of Modena and Reggio Emilia, Italy, approved
the study protocol. Patient informed consent was obtained and patients were appropriately
insured. The study was registered according to European study registration rules (EudraCT:
2009-014137-25), and on ClinicalTrials.gov (Identification number NCT02219646)
Statistical analysis
Statistical analysis was performed through the “per protocol” method. According to the not-
normal distribution of variables, evaluated at Kolmogorov-Smirnov test, the differences of risk
scores were evaluated comparing study and control groups using Mann-Whitney test at each
PDE-5 inhibitors and cardiovascular risk
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visit. The score change during the study protocol was evaluated through Wilcoxon-rank test in
both groups. Moreover, at each visit, the risk change compared to previous visit was calculated.
Finally, each risk was evaluated after adjustment for blood pressure and total, HDL and LDL
cholesterol. The correlation among the risk scores and other parameters was evaluated using
Spearman’s Rho.
Finally, multivariate analyses were performed to detect possible predictors of cardiovascular
risks. Thus, stepwise, linear, multiple regression analyses were performed using each risk score
as dependent variable and age, body mass index, glucose, glycated haemoglobin, microalbumi-
nuria, hs-CRP, IL-6, ET-1, ICAM-1, VCAM-1, fibrinogen, FMD and testosterone as indepen-
dent variables. Each independent variable entered the analysis step by step. In these analyses
lipid profile and blood pressures have not been considered as dependent variables, since they
are included in the algorithms used for cardiovascular risk calculation. All multiple regression
analyses were performed in the study group.
Statistical analysis was performed using the ‘Statistical Package for the Social Sciences’ soft-
ware for Macintosh (version 21.0; SPSS Inc., Chicago, IL). For all comparisons, p values< 0.05
were considered statistically significant.
Results
Fifty-four diabetic men were enrolled, 26 in the study and 28 in the control group. Excluding
drop-outs, 20 patients in the study and 25 in the control group were finally evaluated. Patients
enrolled were similar at baseline for each parameter investigated, as previously reported
(Table 1) [25].
The basal cardiovascular risk at ten years was different using the three algorithms chosen
(p = 0.004), ranging from 12.10±9.30% for the CUORE equation, to 14.86±7.55% for the Fra-
mingham CHD score, to 21.48±7.48% for the ASSIGN equation. At V0, no differences
between study and control groups were found for CHD, MI, stroke, CVD, ASSIGN and
CUORE scores (Table 2). Similarly, no differences were found at V1 (CHD p = 0.405, MI
Table 1. Baseline biochemical characteristics of enrolled patients, evaluated by per protocol analysis.
Normal range Overall Vardenafil Placebo P-value
Number of patients - 45 20 25 -
IIEF-15 –
Erectile function domain
17.17±7.65 16.62±7.90 17.68±7.51 0.614
Glycemia (g/dL) 70–110 138.61±41.21 141.65±47.17 135.79±35.44 0.606
HbA1c (%) 4–6 7.04±1.04 7.09±1.07 6.99±1.02 0.738
Total cholesterol (mg/dL) <200 175.52±36.53 170.38±34.28 180.29±38.50 0.324
HDL cholesterol (mg/dL) >39 42.43±8.23 42.35±7.98 42.50±8.60 0.946
Triglycerides (mg/dL) <180 140.93±66.93 131.00±57.73 150.14±74.33 0.298
LDL cholesterol (mg/dL) <115 104.91±33.44 101.84±30.67 107.76±36.15 0.521
FMD (%) >7 7.38±4.55 6.83±3.89 7.87±5.09 0.308
https://doi.org/10.1371/journal.pone.0199299.t001
Table 2. Basal cardiovascular risk, calculated using the three different equations.
CHD (%) MI (%) STROKE (%) CVD (%) ASSIGN (%) CUORE (%)
Study group 14.22±7.67 8.49±6.43 4.50±4.19 22.75±12.10 19.19±6.90 11.82±9.12
Control group 11.51±7.44 9.66±6.05 4.89±4.19 24.85±11.65 23.07±8.07 12.39±9.49
p-value 0.536 0.497 0.734 0.524 0.767 0.824
Footnotes: CHD: coronary heart disease, MI: myocardial infarction, CVD cardiovascular disease
https://doi.org/10.1371/journal.pone.0199299.t002
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p = 0.372, stroke p = 0.759, CVD p = 0.407, ASSIGN p = 0.708 and CUORE p = 0.668) and V2
(CHD p = 0.455, MI p = 0.327, stroke p = 0.425, CVD p = 0.336, ASSIGN p = 0.809 and
CUORE p = 0.661). No differences among visits were found, considering separately the study
(CHD p = 0.767, MI p = 0.755, stroke p = 0.903, CVD p = 0.862, ASSIGN p = 0.417 and
CUORE p = 0.962) and control (CHD p = 0.806, MI p = 0.849, stroke p = 0.981, CVD
p = 0.951, ASSIGN p = 0.194 and CUORE p = 0.999) group. Similarly, no changes were
observed after adjustment for cholesterol and blood pressure.
Considering the change of each cardiovascular risk estimation from V0 to V1 and from V1
to V2, no differences were found between study and control group.
Endothelial health-related parameters
We previously demonstrated that chronic Vardenafil treatment significantly decreases IL-6
serum levels [25]. Here, we found that IL-6 was not related to cardiovascular risk estimated at
baseline. However, IL-6 was directly related to CHD, CVD and CUORE scores at V1
(Table 3). These correlations remained statistically significant after treatment withdrawal (V2)
for MI and STROKE (Table 3).
Hs-CRP was not related to cardiovascular risk scores at V0 in both study and control
groups (Table 4). However, a significant direct relationship was found at V1 between hs-CRP
and CHD, MI, STROKE, CVD and CUORE only in the study group (Table 4). The significant
correlation between hs-CRP and CHD remained at V2 (Table 4). Interestingly, the direct cor-
relation between hs-CRP and CHD was found also in the control group at V1 and V2
(Table 4).
ET-1, ICAM-1, VCAM-1 and FMD did not correlate with any of the cardiovascular risk
estimations considered, neither in the study, nor in the control group. Similarly, no correla-
tions were found between cardiovascular risk estimation and glycemia-related parameters,
such as serum glucose levels, glycated haemoglobin and microalbuminuria. Finally, the score
at erectile function domain of international index of erectile function (IIEF)-15 did not corre-
late with estimated cardiovascular risk scores in any group.
Table 3. Correlation between IL-6 serum levels and cardiovascular risk scores.
Study group Control group
V0 (n = 26) V1 (n = 20) V2 (n = 20) V0 (n = 28) V1 (n = 25) V2 (n = 23)
Overall cohort
CHD Coefficient 0.180 0.432 0.432 0.213 0.186 0.327
p-value 0.449 0.027 0.047 0.285 0.374 0.128
MI Coefficient 0.146 0.323 0.475 0.148 0.158 0.379
p-value 0.539 0.108 0.035 0.462 0.449 0.074
STROKE Coefficient 0.207 0.382 0.486 0.339 0.129 0.335
p-value 0.380 0.054 0.030 0.082 0.538 0.119
CVD Coefficient 0.194 0.394 0.508 0.234 0.126 0.389
p-value 0.412 0.047 0.022 0.240 0.549 0.066
ASSIGN Coefficient 0.032 0.335 0.197 -0.052 0.036 0.259
p-value 0.894 0.095 0.405 0.797 0.866 0.233
CUORE Coefficient 0.237 0.454 0.601 0.344 0.198 0.418
p-value 0.314 0.020 0.005 0.079 0.344 0.097
Footnotes: CHD: coronary heart disease, MI: myocardial infarction, CVD cardiovascular disease
https://doi.org/10.1371/journal.pone.0199299.t003
PDE-5 inhibitors and cardiovascular risk
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Gonadal status
Testosterone serum levels were not related to any of the estimated cardiovascular risk scores at
V0 in either groups. However, at V1, a significant, inverse relationship between testosterone
and CHD and MI was found only in the study group (Table 5).
Considering gonadal status, we previously demonstrated that 13 of patients enrolled (24%)
were hypogonadal at baseline, according to the cut-off limit (10.4 nmol/L) proposed by the
Endocrine Society [32]. In these men, total testosterone serum levels significantly improved in
the study compared to the control group and across visits [25]. Here, we further strengthen the
association between testosterone and cardiovascular risk. Indeed, considering 7 hypogonadal
men treated with Vardenafil, the inverse relationship at V1 was confirmed between testoster-
one and CHD, MI, CVD and ASSIGN (Table 5). On the contrary, no relationship was found
in the non-hypogonadal men (Table 5).
Multivariate analyses
By multivariate analyses, some significant results were detected. First, considering CHD as
dependent variable, the following equation (p = 0.007) was found: CHD = 12.873+6.178(hs-
CRP). hs-CRP entered also in the second model (p = 0.009), in which the ASSIGN score was
used as dependent variable: ASSIGN = 9.355+39–019(hs-CRP). These results pinpoint vari-
ables are correlated with these parameters which enter in the prediction of cardiovascular risk,
although a direct relationship was not previously pointed out. On the other hand, considering
the CUORE score as dependent variable, IL-6 entered the model (p = 0.009) as follows:
CUORE = 3.454+2560(IL-6).
Discussion
Here, we retrospectively evaluated the effect of chronic Vardenafil administration on the esti-
mation of cardiovascular risk in diabetic men. To the best of our knowledge, this is the first
trial giving the opportunity of evaluating the effect of PDE-5 inhibitors on prediction of
Table 4. Correlation between hs-CRP serum levels and cardiovascular risk scores.
Study group Control group
V0 (n = 26) V1 (n = 20) V2 (n = 20) V0 (n = 28) V1 (n = 25) V2 (n = 23)
Overall cohort
CHD Coefficient 0.396 0.465 0.440 -0.054 0.425 0.433
p-value 0.085 0.039 0.043 0.788 0.034 0.039
MI Coefficient 0.393 0.468 0.322 -0.059 0.392 0.390
p-value 0.091 0.037 0.167 0.771 0.053 0.066
STROKE Coefficient 0.249 0.465 0.131 -0.159 0.110 0.334
p-value 0.220 0.039 0.583 0.428 0.601 0.119
CVD Coefficient 0.364 0.517 0.311 -0.087 0.329 0.321
p-value 0.068 0.020 0.182 0.667 0.108 0.075
ASSIGN Coefficient 0.333 0.294 0.396 0.287 0.276 0.321
p-value 0.096 0.209 0.084 0.146 0.181 0.136
CUORE Coefficient 0.354 0.527 0.350 -0.074 0.225 0.339
p-value 0.076 0.017 0.130 0.714 0.280 0.136
Footnotes: CHD: coronary heart disease, MI: myocardial infarction, CVD cardiovascular disease
https://doi.org/10.1371/journal.pone.0199299.t004
PDE-5 inhibitors and cardiovascular risk
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cardiovascular risk in patients with type 2 diabetes mellitus. In spite of the beneficial effect of
chronic Vardenafil administration on several endothelial health-related parameters [25], no
significant change in the prediction of cardiovascular risk was found using three different algo-
rithms. Of the variables used in these algorhytms, neither cholesterol, nor blood pressure are
directly influenced by Vardenafil administration, as previously demonstrated [25].
The scientific literature demonstrates beneficial effects of PDE-5 inhibitors on cardiac
remodelling [33], symptoms of coronary artery diseases [34] and hemodynamic parameters
[35]. These effects were evaluated in specific clinical conditions, e.g. heart failure, myocardial
infarction, stroke and hypertension [36]. In diabetes mellitus only endothelial health-related
parameters were evaluated after PDE-5 inhibitors treatment [24]. We previously confirmed
the beneficial effect of chronic Vardenafil administration on endothelial parameters, suggested
by a IL-6 reduction and a FMD increase [25]. Whether this beneficial effect could influence
the long-term cardiovascular risk in type 2 diabetes mellitus is not known. Here we do not test
the cardiovascular risk of our patients but whether the prediction of this risk changes under
chronic PDE-5 inhibitor treatment for six months. This parameter does not change. However,
the improvement of endothelial health-related parameters resulting from chronic Vardenafil
Table 5. Correlations between testosterone serum levels and cardiovascular risk scores.
Study group Control group
Overall cohort
V0 (n = 26) V1 (n = 20) V2 (n = 20) V0 (n = 28) V1 (n = 25) V2 (n = 23)
CHD Coefficient -0.040 -0.413 -0.133 0.157 -0.320 0.051
p-value 0.842 0.040 0.544 0.445 0.169 0.830
MI Coefficient -0.053 -0.397 -0.134 0.072 -0.346 -0.018
p-value 0.792 0.049 0.541 0.725 0.135 0.940
STROKE Coefficient 0.002 -0.318 -0.159 0.130 -0.096 -0.114
p-value 0.993 0.121 0.468 0.527 0.686 0.631
CVD Coefficient -0.020 -0.344 -0.110 0.091 -0.284 0.001
p-value 0.921 0.092 0.618 0.657 0.225 0.999
ASSIGN Coefficient -0.019 -0.288 -0.058 -0.010 -0.352 0.015
p-value 0.926 0.163 0.792 0.961 0.128 0.950
CUORE Coefficient -0.118 -0.369 -0.173 0.102 -0.087 0.006
p-value 0.556 0.069 0.430 0.622 0.715 0.980
Hypogonadal men
V0 (n = 7) V1 (n = 6) V2 (n = 6) V0 (n = 6) V1 (n = 4) V2 (n = 4)
CHD Coefficient 0.250 -0.829 -0.257 -0.281 0.034 -0.342
p-value 0.589 0.042 0.623 0.647 0.966 0.778
MI Coefficient 0.250 -0.829 -0.371 -0.274 -0.049 -0.401
p-value 0.589 0.042 0.468 0.655 0.951 0.738
STROKE Coefficient 0.071 -0.314 -0.257 -0.646 0.090 -0.094
p-value 0.879 0.544 0.623 0.239 0.910 0.940
CVD Coefficient 0.143 -0.829 -0.371 -0.376 0.015 -0.294
p-value 0.760 0.042 0.468 0.533 0.985 0.810
ASSIGN Coefficient -0.071 -0.943 -0.486 0.028 0.378 -0.158
p-value 0.879 0.005 0.329 0.965 0.622 0.899
CUORE Coefficient 0.286 -0.314 -0.257 -0.632 0.312 -0.023
p-value 0.535 0.544 0.623 0.252 0.688 0.985
Footnotes: CHD: coronary heart disease, MI: myocardial infarction, CVD cardiovascular disease
https://doi.org/10.1371/journal.pone.0199299.t005
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administration opens the possibility of a stronger effect of this treatment of the predicted car-
diovascular risk using longer treatment duration.
A direct relationship between hs-CRP and cardiovascular risk scores is found in study
group at V1, although hs-CRP did not change over time and after Vardenafil administration,
as previously reported [25]. This result suggests that hs-CRP could have an important role on
the parameters used in the prediction of cardiovascular risk. On the contrary, other endothelial
health-related parameters, which are strongly influenced by Vardenafil administration (e.g.
FMD) [25], are not related to the estimated cardiovascular risk scores. These relationships sug-
gest that cardiovascular risk predicted by validated tools seems to be mostly related to inflam-
mation markers, rather than to vasodilator parameters. As a confirmation, multivariate
analyses highlight the hs-CRP and IL-6 role in the prediction of cardiovascular risk. Thus,
since the PDE-5 inhibitors anti-inflammatory effect was proven by previous results, we might
expect them to exert a protective role on cardiovascular risk provided the treatment is suffi-
ciently long. However, the clinical use of these drugs for this purpose is not indicated so far
and properly designed, longer and well-powered clinical trials are needed to better understand
long-term survival of these patients after longer chronic treatment. In this context, the role of
sphingosine-1-phosphate is widely proposed and a possible combined effect with PDE-5 inhib-
itors could be evaluated in the near future [37, 38].
Finally, cardiovascular risk predicted by validated algorithms seems to be influenced by
total testosterone serum levels. In particular, CHD and MI are inversely related to testosterone
after Vardenafil administration. This correlation is further confirmed considering only dia-
betic men with hypogonadism at baseline. Since chronic Vardenafil administration improves
testosterone serum levels in hypogonadal diabetic men [25], this might be another way by
which gonadal function improvement results in a beneficial effect on cardiovascular health.
Therefore, the overall protective role of PDE-5 inhibitors on cardiovascular health might be
mediated by both inflammatory markers decrease and gonadal function improvement.
A large number of cardiovascular risk calculators have been developed and validated so far,
the first and widely used tool being represented by the Framingham score [11], which how-
ever, suffers of a number of pitfalls. Indeed, it is well demonstrated that the use of this calcula-
tor for deciding whether preventive therapy is needed or not could lead to under-treatment
with a consequent socio-economic burden increase [39]. Thus, other equations have been
developed and validated in different population-based cohorts. Although these algorithms
should provide overlapping scores, we found different percentages of the estimated cardiovas-
cular risk at ten years considering the same group of patients, ranging from 12% for the
CUORE score, to 22% for the ASSIGN equation. Thus, our results confirm the discrepancy in
the risk prediction obtained by different algorithms and how to generalize the risk score
obtained by these calculators remains the main challenge in this field. Moreover, the clinical
use of these algorithms must consider the characteristics of the population in which the tool
has been validated. Admittedly, our study, which was not designed to assess the cardiovascular
risk and solve these discrepancies, is bases on a low number of patients enrolled and relatively
short-term treatment therapy length to investigate appropriately the effects of PDE-5 inhibi-
tors. However, our retrospective analysis gives some hints, which could be useful for the design
of future prospective studies in cardiovascular prevention in diabetic patients and for the iden-
tification of the best predictive tool in this setting.
The strength of the present study relies on the study design of the original trial (prospective,
double blind, placebo controlled), which provided the longest treatment duration with a PDE-
5 inhibitor and follow-up phase published so far. Admittedly, however, the treatment duration
is at the same time a potential limit for the parameter investigated here. Indeed, cardiovascular
PDE-5 inhibitors and cardiovascular risk
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risk is predicted at ten years and longer treatment durations might be necessary to influence
this parameter. Finally, the low number of patients represents another important limit.
In conclusion, despite six-months of chronic Vardenafil administration do not change car-
diovascular risk prediction, a beneficial effect of PDE-5 inhibitors on cardiovascular health, via
the previously demonstrated action on inflammatory markers is suggested. Similarly, the
PDE-5 inhibitors effect in restoring normal gonadal function seems to influence the prediction
of long term cardiovascular risk. Longer duration of chronic PDE-5 inhibitors treatment
should be evaluated in the near future.
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